Program
mirikizumab
Also written as “Mirikizumab”, “LY3074828” and “Mirikizumab IV”.
Its studies are mostly in Colitis, Ulcerative · Psoriasis · Crohn Disease · Breast Feeding, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 356 open or running | phase 4since May 21, 2026 | Sep 18, 2013 | Feb 2027phase 1 · NCT07446101 |
| Rubix LS | 11 open or running | phase 4since Jul 1, 2025 | Jul 1, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 22 studies since Sep 18, 2013.
- Jul 10, 2020Phase 3 study in Colitis, UlcerativeEli Lilly · NCT04469062
- Sep 10, 2020Phase 1 study in HealthyEli Lilly · NCT04548219 · 60 enrolled · United States
- Oct 28, 2020Phase 1 study in HealthyEli Lilly · NCT04607733 · 240 enrolled · United States
- Apr 12, 2021Phase 3 study in Colitis, UlcerativeEli Lilly · NCT04844606 · 150 planned · United States, Austria, Belgium and more
- Oct 1, 2021Phase 1 study in HealthyEli Lilly · NCT05069896 · 237 enrolled · United States
- Aug 19, 2022Phase 3 study in Crohn DiseaseEli Lilly · NCT05509777 · 90 planned · United States, Austria, Belgium and more
- Aug 24, 2022Phase 1 study in HealthyEli Lilly · NCT05515601 · 396 enrolled · United States
- Dec 1, 2022Phase 1 study in HealthyEli Lilly · NCT05644353 · 450 enrolled · United States
- Feb 8, 2023Phase 3 study in Colitis, UlcerativeEli Lilly · NCT05767021 · 172 enrolled · United States, Belgium, Czechia and more
- Mar 13, 2023Phase 3 study in Colitis, UlcerativeEli Lilly · NCT05784246 · 63 enrolled · United States, Belgium, Canada and more
- Jun 21, 2024Phase 1 study in HealthyEli Lilly · NCT06475729 · 498 enrolled · United States
- Jul 1, 2025Rubix LS's first study: phase 4 study in Crohn DiseaseNew to Rubix LSRubix LS · NCT07059130 · 150 planned · United States
- Feb 26, 2026Phase 1 study in HealthyEli Lilly · NCT07446101 · 450 planned · United States
- May 21, 2026Phase 4 study in Breast FeedingEli Lilly · NCT07612267 · 14 planned · United States, Canada, Denmark and more
Ahead
- Feb 2027Primary completion: phase 1 study in HealthyEli Lilly · NCT07446101
- Dec 2027Primary completion: phase 3 study in Crohn DiseaseEli Lilly · NCT05509777
- Sep 2028Primary completion: phase 4 study in Breast FeedingEli Lilly · NCT07612267
- Dec 2030Primary completion: phase 3 study in Colitis, UlcerativeEli Lilly · NCT04844606
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risankizumabrule | AbbVie | phase 4 | 68 |
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07612267Breast Feeding · United States, Canada, Denmark and more | 4 | Recruiting | Eli Lilly | Sep 2028 | 14 |
| NCT07446101Healthy · United States | 1 | Recruiting | Eli Lilly | Feb 2027 | 450 |
| NCT07059130Crohn Disease · United States | 4 | Not yet recruiting | Rubix LS | Jan 1, 2026 | 150 |
| NCT06475729Healthy · United States | 1 | Completed | Eli Lilly | Dec 27, 2024 | 498 |
| NCT05784246Colitis, Ulcerative · United States, Belgium, Canada and more | 3 | Completed | Eli Lilly | May 1, 2026 | 63 |
| NCT05767021Colitis, Ulcerative · United States, Belgium, Czechia and more | 3 | Completed | Eli Lilly | Aug 9, 2024 | 172 |
| NCT05644353Healthy · United States | 1 | Completed | Eli Lilly | May 25, 2023 | 450 |
| NCT05515601Healthy · United States | 1 | Completed | Eli Lilly | Feb 20, 2023 | 396 |
| NCT05509777Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | Dec 2027 | 90 |
| NCT05069896Healthy · United States | 1 | Completed | Eli Lilly | Jun 22, 2022 | 237 |
| NCT04844606Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | Dec 2030 | 150 |
| NCT04607733Healthy · United States | 1 | Completed | Eli Lilly | May 17, 2021 | 240 |
| NCT04548219Healthy · United States | 1 | Completed | Eli Lilly | Jan 11, 2021 | 60 |
| NCT04469062Colitis, Ulcerative | 3 | Withdrawn | Eli Lilly | Mar 13, 2024 | 0 |
| NCT04232553Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Nov 28, 2024 | 996 |
| NCT04137380Healthy · China | 1 | Completed | Eli Lilly | Dec 11, 2020 | 60 |
| NCT04004611Colitis, Ulcerative · United States, Canada, Israel and more | 2 | Completed | Eli Lilly | Mar 15, 2023 | 26 |
| NCT03926130Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Aug 23, 2023 | 1,158 |
| NCT03718884Psoriasis · United States | 1 | Completed | Eli Lilly | Oct 28, 2019 | 29 |
| NCT03748940Healthy · United Kingdom | 1 | Completed | Eli Lilly | Jun 18, 2019 | 60 |
| NCT03662100Healthy · United States | 1 | Completed | Eli Lilly | Jan 25, 2019 | 66 |
| NCT03556202Psoriasis · United States, Argentina, Australia and more | 3 | Terminated | Eli Lilly | Feb 7, 2022 | 1,936 |
| NCT03535194Psoriasis · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Mar 5, 2020 | 1,484 |
| NCT03524092Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Nov 3, 2021 | 1,328 |
| NCT03519945Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Mar 4, 2026 | 1,058 |
| NCT03518086Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jan 21, 2021 | 1,281 |
| NCT03482011Psoriasis · United States, Germany, Japan and more | 3 | Completed | Eli Lilly | Mar 21, 2019 | 530 |
| NCT03456713Healthy · United States | 1 | Completed | Eli Lilly | Aug 13, 2018 | 72 |
| NCT03220126Healthy · United Kingdom | 1 | Completed | Eli Lilly | Feb 23, 2018 | 72 |
| NCT03188510Healthy · United States | 1 | Completed | Eli Lilly | Nov 27, 2017 | 54 |
| NCT03053622Healthy · United Kingdom | 1 | Completed | Eli Lilly | Apr 3, 2018 | 67 |
| NCT02899988Plaque Psoriasis · United States, Canada, Germany and more | 2 | Completed | Eli Lilly | Jun 19, 2017 | 205 |
| NCT02891226Crohn Disease · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Dec 11, 2018 | 191 |
| NCT02589665Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Dec 19, 2017 | 249 |
| NCT02568423Healthy · United States | 1 | Completed | Eli Lilly | Jul 16, 2018 | 51 |
| NCT01947933Psoriasis · Canada | 1 | Completed | Eli Lilly | Feb 2015 | 45 |
How it is read
Names in the registry
- “Mirikizumab”, 24 entries
- “LY3074828”, 6 entries
- “Mirikizumab IV”, 3 entries
- “Mirikizumab SC”, 3 entries
- “Mirikizumab - SC”, 3 entries
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 9 studies
- Psoriasis, 6 studies
- Crohn Disease, 5 studies
- Breast Feeding, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.